Update on the Role of Toll-like Receptors During Bacterial Infections and Sepsis

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2010 Apr 6

PMID 20364412

Citations 15

Authors

Sylvia Knapp

Affiliations

Soon will be listed here.

Abstract

Toll-like receptors (TLRs) are recognition molecules that importantly contribute to the innate immune response to bacterial and viral infections. Once TLRs sense the presence of invading pathogens a signal transduction cascade is initiated that eventually leads to the production of pro-inflammatory mediators and attraction of neutrophils to the site of infection. While the ultimate goal of this defense pathway is the successful elimination of invading microbes, prolonged or exaggerated stimulation of TLR-associated events can lead to systemic inflammation and clinical symptoms of sepsis. This brief review summarizes the impact of selected TLRs in the host response to clinically important bacteria and provides insights into TLR-associated therapeutic approaches during sepsis and inflammation.

Citing Articles

TLR4 knockdown by miRNA-140-5p improves tendinopathy: an study.

Jun T, Ruipeng G, Bin X Arch Med Sci. 2024; 20(2):582-601.

PMID: 38757029 PMC: 11094843. DOI: 10.5114/aoms.2020.93216.

A phospho-tyrosine-based signaling module using SPOP, CSK, and LYN controls TLR-induced IRF activity.

Tawaratsumida K, Redecke V, Wu R, Kuriakose J, Bouchard J, Mittag T Sci Adv. 2022; 8(27):eabq0084.

PMID: 35857476 PMC: 9269885. DOI: 10.1126/sciadv.abq0084.

Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.

Farooq M, Batool M, Kim M, Choi S Front Cell Dev Biol. 2021; 9:756315.

PMID: 34671606 PMC: 8522911. DOI: 10.3389/fcell.2021.756315.

Enriched environment housing improved the laying hen's resistance to transport stress via modulating the heat shock protective response and inflammation.

Li C, Zhang R, Wei H, Wang Y, Chen Y, Zhang H Poult Sci. 2021; 100(3):100939.

PMID: 33652541 PMC: 7936215. DOI: 10.1016/j.psj.2020.12.036.

Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients.

Zeng Q, Wu J, Yang S J Clin Lab Anal. 2019; 33(4):e22836.

PMID: 30803045 PMC: 6528565. DOI: 10.1002/jcla.22836.

References

Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock D . Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008; 180(5):3478-84. DOI: 10.4049/jimmunol.180.5.3478. View

Brentano F, Schorr O, Gay R, Gay S, Kyburz D . RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005; 52(9):2656-65. DOI: 10.1002/art.21273. View

Pugin J, Stern-Voeffray S, Daubeuf B, Matthay M, Elson G, Dunn-Siegrist I . Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood. 2004; 104(13):4071-9. DOI: 10.1182/blood-2003-04-1290. View

Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A . Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005; 202(11):1575-85. PMC: 2213330. DOI: 10.1084/jem.20051696. View

Takeda K, Kaisho T, Akira S . Toll-like receptors. Annu Rev Immunol. 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126. View

Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol. 2002; 1(2):135-45. DOI: 10.1038/35100529. View

Visintin A, Mazzoni A, Spitzer J, Segal D . Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A. 2001; 98(21):12156-61. PMC: 59784. DOI: 10.1073/pnas.211445098. View

Takeuchi O, Hoshino K, Akira S . Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol. 2000; 165(10):5392-6. DOI: 10.4049/jimmunol.165.10.5392. View

Qureshi S, Lariviere L, Leveque G, Clermont S, Moore K, Gros P . Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999; 189(4):615-25. PMC: 2192941. DOI: 10.1084/jem.189.4.615. View

10.

Tian J, Avalos A, Mao S, Chen B, Senthil K, Wu H . Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007; 8(5):487-96. DOI: 10.1038/ni1457. View

11.

Leadbetter E, Rifkin I, Hohlbaum A, Beaudette B, Shlomchik M, Marshak-Rothstein A . Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002; 416(6881):603-7. DOI: 10.1038/416603a. View

12.

Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T . Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 1999; 11(4):443-51. DOI: 10.1016/s1074-7613(00)80119-3. View

13.

Miyake K . Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007; 19(1):3-10. DOI: 10.1016/j.smim.2006.12.002. View

14.

Imai Y, Kuba K, Neely G, Yaghubian-Malhami R, Perkmann T, van Loo G . Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008; 133(2):235-49. PMC: 7112336. DOI: 10.1016/j.cell.2008.02.043. View

15.

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y . Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005; 11(11):1173-9. DOI: 10.1038/nm1315. View

16.

Park J, Svetkauskaite D, He Q, Kim J, Strassheim D, Ishizaka A . Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2003; 279(9):7370-7. DOI: 10.1074/jbc.M306793200. View

17.

Bernard G, Vincent J, Laterre P, LaRosa S, Dhainaut J, Lopez-Rodriguez A . Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344(10):699-709. DOI: 10.1056/NEJM200103083441001. View

18.

Levi M, van der Poll T . Recombinant human activated protein C: current insights into its mechanism of action. Crit Care. 2008; 11 Suppl 5:S3. PMC: 2230607. DOI: 10.1186/cc6154. View

19.

ONeill L, Bryant C, Doyle S . Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009; 61(2):177-97. PMC: 2846156. DOI: 10.1124/pr.109.001073. View

20.

Barton G, Kagan J . A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009; 9(8):535-42. PMC: 3934928. DOI: 10.1038/nri2587. View